Clinical Trial Update: Zanubrutinib Plus R-CHOP for Patients With Newly Diagnosed Untreated Non-GCB DLBCL [Phase 2]

View source ↗

Summary

Phase 2 trial update investigating zanubrutinib in combination with R-CHOP for newly diagnosed untreated non-GCB/ABC diffuse large B-cell lymphoma (DLBCL).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma
• Non-hodgkin Lymphoma

Drugs mentioned

• R-CHOP
• Zanubrutinib (zanubrutinib)

Snippet

Sponsor: The First Affiliated Hospital of Soochow University | Conditions: Non-GCB/ABC Diffuse Large B-Cell Lymphoma | Phase 2 | Status: UNKNOWN